Tagged with P

China It has been announced by China’s State Council that as of March 1st 2019, the government will reduce the VAT on a “first batch” of 21 rare disease drugs and four active pharmaceutical ingredients (API’s) by more than 80% in a bid to get new treatments to market faster. Historically, China has…

China This is the first in a series of articles examining what it takes to be a country manager of a multinational pharma company in some of the world’s most challenging markets. We start in China, where the heads of Merck, Ipsen, Chiesi, Gedeon Richter and AbbVie’s Chinese affiliates give their…

GW Pharma Founded in 1998, GW Pharmaceuticals is a British biopharmaceutical company, best known for being the only company with a license to cultivate cannabis in the UK. True pioneers, they are the producers of Sativex and Epiodiolex, the former being the world’s first prescription medicine derived from the cannabis plant —…

Egypt Hassan Behnam, managing director of the French Chamber of Commerce and Industry in Egypt explains the investment opportunities Egypt has to offer, examines the close relationship between Egypt and France and highlights the recent visit of French President Emmanuel Macron to Egypt.   We at the French Chamber firmly believe…

France Biotest’s Olivier Samama outlines the changes that the takeover of the company has had on the French affiliate, the country’s plasma market and pricing policy.   The product offering remains essentially the same, but we have experienced rapid double-digit growth in the last 3 years in viral infectious disease after…

Korea Looking at what it takes to be a country manager of a multinational pharma company in some of the world’s most challenging markets. DHR International’s Helen Park outlines what she looks for in potential candidates for country manager positions in South Korea.   What are the qualities you look for…

Europe The 9th February 2019 marked the launch of the European Medicines Verification System (EMVS) which will use cutting-edge technology to safeguard the medicine supply chain against fake products.   Each European country has to implement a National Medicines Verification System – EMVS   The new system — which is being dubbed the…

Switzerland Jane Griffiths, global head of Actelion – acquired in 2017 by Johnson & Johnson – discusses her priorities heading up an iconic rare disease-focused biotech and gives her take on a wide range of hot-button industry issues; from the future of M&As to patient-centricity, women in leadership and digital disruption.…

Spain María Jesús Lamas, director and César Hernández García, head of medicines for human use at the Spanish Agency of Medicine and Health Products (AEMPS), discuss the challenges impacting the evaluation and analysis of products today. Furthermore, they give insights into why Spain is a leading global clinical trials destination and…

France The healthcare and life sciences industries, as they become more advanced and complex, increasingly require government involvement to ensure clinical compliance, ethical behaviour and the well-being of the nation. The health sector is subject to mounting regulatory pressures meaning politics must play a key role. As we advance more and more in healthcare…

China Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis. Together with his colleague Sarah Hassan, a researcher at the company they look at China’s skyrocketing health industry and what to expect from it in the Year of the Pig, 2019.    China approved a record 48 new drugs last year, despite a significant organizational restructuring.…

Korea Syneos Health, established through a merger in 2017, has held a foothold in Korea through its legacy organisations for over 10 years. Sora Lee, general manager of Syneos Korea, provides her assessment of the impact of the merger. She also comments on Syneos Health’s MoU with KoNECT (Korea National Enterprise…